CPI-444, a selective A2AR inhibitor, was used as a mono-drug or combined with atezolizumab (anti-PD-L1 antibody) for the therapies of patients with advanced non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), melanoma, and triple negative breast cancer (TNBC) (NCT02655822). Here, CD274 is linked to non-small cell lung carcinoma.